Journal: Journal of Personalized Medicine

Article Title: The Role of Nodes and Nodal Assessment in Diagnosis, Treatment and Prediction in ER+, Node-Positive Breast Cancer

doi: 10.3390/jpm13101476

Figure Lengend Snippet: Predictive gene tests used in breast cancer care.

Article Snippet: EndoPredict (EP)/EPclin , Myriad Genetics , 12 , RT-qPCR , RNA from FFPE tumour tissue , Postmenopausal women with early HR+/HER2 breast cancer who have been on ET for 5 years , Yes (1–3 positive nodes) , EP score , EP score of 0 to <5 low risk, EP 5 to 15 high risk; EPclin < 3.3 low risk, EPclin ≥ 3.3 high risk , Benefit from adjuvant chemotherapy , Risk of distant and late recurrence after 10 and 15 years.

Techniques: Adjuvant, Microarray, Immunohistochemistry

Journal: Therapeutic Advances in Medical Oncology

Article Title: The clinical utility of gene expression assays in breast cancer patients with 0–3 involved lymph nodes

doi: 10.1177/17588359211038467

Figure Lengend Snippet: Commercially available multiparameter gene expression assays.

Article Snippet: This review will summarize the clinical utility of several commonly used multiparameter gene expression assays , including the Oncotype DX Recurrence Score (RS) (Genomic Health, Exact Sciences, Madison WI), MammaPrint (Agendia, Inc., Irvine, CA), PAM50 Risk of Recurrence (ROR) score (Prosigna, Veracyte, San Francisco, CA), EndoPredict (EP) (Myriad Genetics, Salt Lake City, UT), and Breast Cancer Index (BCI) (Biotheranostics, Inc., San Diego, CA), in early hormone receptor-positive (HR+) HER2 negative BCA.

Techniques: Gene Expression

Journal: Therapeutic Advances in Medical Oncology

Article Title: The clinical utility of gene expression assays in breast cancer patients with 0–3 involved lymph nodes

doi: 10.1177/17588359211038467

Figure Lengend Snippet: Selected clinical trials evaluating gene expression assays.

Article Snippet: This review will summarize the clinical utility of several commonly used multiparameter gene expression assays , including the Oncotype DX Recurrence Score (RS) (Genomic Health, Exact Sciences, Madison WI), MammaPrint (Agendia, Inc., Irvine, CA), PAM50 Risk of Recurrence (ROR) score (Prosigna, Veracyte, San Francisco, CA), EndoPredict (EP) (Myriad Genetics, Salt Lake City, UT), and Breast Cancer Index (BCI) (Biotheranostics, Inc., San Diego, CA), in early hormone receptor-positive (HR+) HER2 negative BCA.

Techniques: Clinical Proteomics, Gene Expression, Adjuvant, Comparison

Journal: Therapeutic Advances in Medical Oncology

Article Title: The clinical utility of gene expression assays in breast cancer patients with 0–3 involved lymph nodes

doi: 10.1177/17588359211038467

Figure Lengend Snippet: Clinical practice guidelines for use of gene expression assays to guide adjuvant chemotherapy recommendations.

Article Snippet: This review will summarize the clinical utility of several commonly used multiparameter gene expression assays , including the Oncotype DX Recurrence Score (RS) (Genomic Health, Exact Sciences, Madison WI), MammaPrint (Agendia, Inc., Irvine, CA), PAM50 Risk of Recurrence (ROR) score (Prosigna, Veracyte, San Francisco, CA), EndoPredict (EP) (Myriad Genetics, Salt Lake City, UT), and Breast Cancer Index (BCI) (Biotheranostics, Inc., San Diego, CA), in early hormone receptor-positive (HR+) HER2 negative BCA.

Techniques: Gene Expression, Adjuvant